Tesamorelin vs Selank
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Selank
Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia for anxiety and cognitive enhancement.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Selank |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Modulates the expression of brain-derived neurotrophic factor (BDNF) and affects serotonin and norepinephrine systems. Has immunomodulatory and anxiolytic properties. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Intranasal administration: 250-500mcg 2-3 times daily. Subcutaneous: 250-500mcg daily. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Most commonly administered intranasally for cognitive effects. Can also be injected subcutaneously. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Generally well-tolerated. Some users report mild fatigue or nasal irritation with intranasal use. |
| Best For |